Posts Tagged 'new research'

Blood Pressure Drugs May Reduce Risk of Alzheimer’s and Dementia

Angiotensin receptor blockers, prescription drugs commonly used to treat high blood pressure and heart disease, may help reduce the risk of Alzheimer’s disease and dementia, new research is suggesting.

The study also demonstrated that angiotensin receptor blockers appear to provide a higher level of protection against Alzheimer’s disease and dementia in comparison to other high blood pressure and heart disease medication. This research is the first large scale study on whether angiotensin receptor blockers can reduce the risk of developing dementia and Alzheimer’s disease.

Dementia, which includes Alzheimer’s disease, continues to threaten a growing number of people as they age. The disease can also cause huge economic problems due to the long periods of time patients with the disease must spend in nursing homes.

While dementia and Alzheimer’s disease remain to be complex diseases, researchers have found increasing evidence for three main risk factors: age, genetics and heart disease. In particular, mid-life diseases such as diabetes and high blood pressure appear to be related to a higher chance of developing dementia.

Professor Benjamin Wolozin from Boston University School of Medicine, the researcher leading the study, and colleagues analyzed the incidence of dementia in over 800,000 mostly male (98%) subjects in America from 2002 to 2006. Each participant had cardiovascular disease and was over the age of 65 years old. One group of patients used angiotensin receptor blockers, a second group used lisinopril, a drug that helps lower blood pressure, and a third used other comparative drugs generally used for heart disease.

Results show that the group using angiotensin receptor blockers were considerably less likely to develop Alzheimer’s disease or dementia. Angiotensin receptor blockers also have an additive effect while used with another type of high blood pressure drug (ACE inhibitors). Patients who were already diagnosed with Alzheimer’s disease or dementia were less likely to die early or enter nursing homes while taking both prescription medicines.

This research is important to continue because it is the “first to compare both risk of dementia and progression of dementia in users of angiotensin receptor blockers compared with users of a drug from the same class (lisinopril) or users of other drugs prescribed for cardiovascular disease” says Wolozin.

Finding an effective way of preventing dementia is one of the top priorities for public health. However, further study is needed to validate the effectiveness of antihypertensives in general and angiotensin receptor blockers in particular, researchers conclude.

For more information on Alzheimer’s disease or dementia related prescription drugs, visit www.orderonlinedrugs.com

Angiotensin receptor blockers, prescription drugs commonly used to treat high blood pressure and heart disease, may help reduce the risk of Alzheimer’s disease and dementia, new research is suggesting.

The study also demonstrated that angiotensin receptor blockers appear to provide a higher level of protection against Alzheimer’s disease and dementia in comparison to other high blood pressure and heart disease medication. This research is the first large scale study on whether angiotensin receptor blockers can reduce the risk of developing dementia and Alzheimer’s disease.

Dementia, which includes Alzheimer’s disease, continues to threaten a growing number of people as they age. The disease can also cause huge economic problems due to the long periods of time patients with the disease must spend in nursing homes.

While dementia and Alzheimer’s disease remain to be complex diseases, researchers have found increasing evidence for three main risk factors: age, genetics and heart disease. In particular, mid-life diseases such as diabetes and high blood pressure appear to be related to a higher chance of developing dementia.

Professor Benjamin Wolozin from Boston University School of Medicine, the researcher leading the study, and colleagues analyzed the incidence of dementia in over 800,000 mostly male (98%) subjects in America from 2002 to 2006. Each participant had cardiovascular disease and was over the age of 65 years old. One group of patients used angiotensin receptor blockers, a second group used lisinopril, a drug that helps lower blood pressure, and a third used other comparative drugs generally used for heart disease.

Results show that the group using angiotensin receptor blockers were considerably less likely to develop Alzheimer’s disease or dementia. Angiotensin receptor blockers also have an additive effect while used with another type of high blood pressure drug (ACE inhibitors). Patients who were already diagnosed with Alzheimer’s disease or dementia were less likely to die early or enter nursing homes while taking both prescription medicines.

This research is important to continue because it is the “first to compare both risk of dementia and progression of dementia in users of angiotensin receptor blockers compared with users of a drug from the same class (lisinopril) or users of other drugs prescribed for cardiovascular disease” says Wolozin.

Finding an effective way of preventing dementia is one of the top priorities for public health. However, further study is needed to validate the effectiveness of antihypertensives in general and angiotensin receptor blockers in particular, researchers conclude.

For more information on Alzheimer’s disease or dementia related prescription drugs, visit www.orderonlinedrugs.com

Painkiller Celebrex May Reduce Risk of Skin Cancer

People with a family history of a skin disorder may be able to reduce the risk of developing skin cancer simply by taking the painkiller and prescription drug celecoxib (Celebrex), new research is suggesting. The study is still in preliminary stages and the drug is not yet approved for this specific use, but results look promising.

The skin disorder, called Gorlin syndrome, usually causes a patient to develop hundreds or thousands of cancerous lesions (basal cell carcinomas). Researchers chose to study this particular form of skin cancer because their goal was to find an element in these high-risk patients that could be transferable to the “normal” population. This could then allow for a form of chemoprevention that could decrease the rate of skin cancers in every person.

Researchers studied patients with basal cell carcinoma who took 200mgs of Canadian prescription drug Celebrex twice a day. Dr. Ervin H. Epstein Jr., senior scientist at the Children’s Hospital of Oakland Research Institute in California reported that these patients had a significantly lower amount of lesions after two years compared to those who were taking a placebo.

However, Celebrex has been found to increase cardiovascular side effects and more research is needed in order to prove its safety.

These findings can be found in the January issue of Cancer Prevention Research. For more of the latest prescription drug and medical research news, visit www.orderonlinedrugs.com



Follow

Get every new post delivered to your Inbox.